p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer

British Journal of Cancer

Volumn 74, Issue 1, 1996, Pages 63-68

  Linn, S C ^a   Honkoop, A H ^a   Hoekman, K ^a   Van Der Valk, P ^a   Pinedo, H M ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Multidrug resistance; P glycoprotein; p53; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN P53;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030015546     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.316     Document Type: Article

References (28)

1. ALLRED DC, CLARK GM, ELLEDGE R, FUQUA SAW, BROWN RW, CHAMNESS GC, OSBORNE CK AND MCGUIRE WL. (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl Cancer Inst., 85, 200-206.
2. CHAN HSL, HADDAD G, THORNER PS, DEBOER G, LIN YP, ONDRUSEK N, YEGER H AND LING V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med., 325, 1608-1614.
3. CHARPIN C, VIELH P, DUFFAUD F, DEVICTOR B, ANDRAC L, LAVAUT MN, ALLASIA C, HORSCHOWSKI N AND PIANA L. (1994). Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl Cancer Inst., 86, 1539-1545.
4. CHIN K-V, UEDA K, PASTAN I AND GOTTESMAN MM. (1992). Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science, 255, 459-462.
5. COX DR. (1972). Regression models and life tables. J. Roy. Stat. Soc. Br., 34, 187-220.
6. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet, 339, 1-15; 71-84.
7. FUJIWARA T, GRIMM EA, MUKHOPADHYAY T, ZHANG W-W, OWEN-SCHAUB LB AND ROTH JA. (1994). Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291.
8. GREENBLATT MS, BENNETT WP, HOLLSTEIN M AND HARRIS CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
9. HARRIS JR, LIPPMAN ME, VERONESI U AND WILLETT W. (1992). Breast cancer. N. Engl. J. Med., 327, 319-328; 390-398; 473-480.
10. HOEKMAN K, WAGSTAFF J, VAN GROENINGEN CJ, VERMORKEN JB, BOVEN E AND PINEDO HM. (1991). Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J. Natl Cancer Inst., 83, 1546-1553.
11. JACQUEMIER J, MOLES JP, PENAULT-LLORCA F, ADELAIDE J, TORRENTE M, VIENS P, BIRNBAUM D AND THEILLET C. (1994). p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer, 69, 846-852.
12. KAPLAN E AND MEIER P. (1958). Non parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
13. KEITH WN, STALLARD S AND BROWN R. (1990). Expression of mdr1 and gst-π in human breast tumors: comparison to in vitro chemosensitivity. Br. J. Cancer, 61, 712-716.
14. LOWE SW, RULEY HE, JACKS T AND HOUSMAN DE. (1993). p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
15. LOWE SW, BODIS S, McCLATCHEY A, REMINGTON L, RULEY HE, FISHER DE, HOUSMAN DE AND JACKS T. (1994). p53 Status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
16. MANTEL N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-170.
17. MULLINK H, HENZEN-LOGMANS SC, ALONS-VAN KORDELAAR JJM, TADEMA TM AND MEIJER CJ. (1986). Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virch. Arch. (Cell. Pathol.), 52, 55-65.
18. SALMON SE, GROGAN TM, MILLER T, SCHEPER R AND DALTON WS. (1989). Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein. J. Natl Cancer Inst., 81, 696-701.
19. SANFILIPPO O, RONCHI E, DE MARCO C, DI FRONZO G AND SILVESTRINI R. (1991). Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer, 7, 155-158.
20. SCHEPER RJ, BULTE JWM, BRAKKEE JGP, QUAK JJ, VAN DER SCHOOT E, BALM AJM, MEIJER CJLM, BROXTERMAN HJ, KUIPER CM, LANKELMA J AND PINEDO HM. (1988). Monoclonal antibody JSB-I detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int. J. Cancer, 42, 389-394.
21. SCHNEIDER J, BAK M, EFFERTH TH, KAUFMANN M, MATTERN J AND VOLM M. (1989). P-glycoprotein expression in treated and untreated human breast cancer. Br. J. Cancer, 60, 815-818.
22. SCHNEIDER J, RUBIO M-P, BARBAZAN M-J, RODRIGUEZ-ESCUDERO J, SEIZINGER BR AND CASTRESANA JS (1994). P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl Cancer Inst., 86, 850-855.
23. SHI S-R, KEY ME AND KALRA KL. (1991). Antigen retrieval in formalin-fixed, paraffin-embedded tissues. An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39, 741-748.
24. THOR AD, MOORE II DH, EDGERTON SM, KAWASAKI ES, REIHSAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN L-C, MAYALL BH AND SMITH HS. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845-855.
25. VAN DER VALK P, VAN KALKEN CK, KETELAARS H, BROXTERMAN HJ, SCHEFFER G, KUIPER CM, TSURUO T, LANKELMA J, MEIJER CJLM, PINEDO HM AND SCHEPER RJ. (1990). Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol., 1, 56-64.
26. VAN KALKEN CK, PINEDO HM AND GIACCONE G. (1991). Multidrug resistance from the clinical point of view. Eur. J. Cancer, 27, 1481-1486.
27. VERELLE P, MEISSONNIER F, FONCK Y, FEILLEL V, DIONET C, KWIATKOWSKI F, PLAGNE R AND CHASSAGNE J. (1991). Clinical relevance of immunohistochemical detection of multidrug resistance of P-glycoprotein in breast carcinoma. J. Natl Cancer Inst., 83, 111-116.
28. WISHART GC, PLUMB JA, GOING JJ, et al. (1990). P-glycoprotein expression in primary breast cancer detected by immunohistochemistry with two monoclonal antibodies. Br. J. Cancer, 62, 758-761.